ClinicalTrials.gg
WithdrawnNCT00456313Updated Apr 17, 2015

No Resistance After Long Term Treatment SERETIDE

A Phase 4 interventional study of FLIXOTIDE and SERETIDE in Asthma, sponsored by GlaxoSmithKline. Withdrawn at 2 sites in Netherlands. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2015-04-17.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Why this study was withdrawn
lack of data

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
141st of 146
0 · median 100
Started
2007
with 17 others
Phase 4
52 of 147
1 open now
Registered
36th of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 141st largest by enrollment of the 146 interventional ones that give a count, is one of 18 that started in 2007, is one of 52 in phase 4, and was the 36th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This multi centre, double blind, comparator controlled, parallel group study is to determine whether asthma treatment with high doses of fluticasone propionate (FP) redirects a Th2/ eosinophil response towards a more treatment resistant neutrophil/ monocyte response and whether this occurs to a lesser extent in asthmatic subjects treated with the combination product of salmeterol and fluticasone propionate (SFC). The primary endpoint is the mean change in priming of blood neutrophils assessed by marker A17. After a run-in period of 4 weeks subjects will enter a 24 weeks high dose treatment (FP 500 mcg bd) or a 12 week medium-dose treatment with FP 250 mcg bd followed by a 12 week treatment with SFC 50/ 250 mcg. At the visits lung function measurements, ACT, eNO measurements and a blood sample will be performed. A total of 50 randomised subjects are planned to be recruited in this study

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • fluticasone propionate
  • salmeterol/fluticasone propionate
  • combination product
  • innate immune response
  • neutrophil priming
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion:

  • Positive skin prick test
  • History of asthma (GINA)
  • Regular treatment with FP with/without LABA at least 4 weeks before visit 1
  • History of recurrent episodes of wheezing, breathlessness, chest tightness and/ or coughing in the previous year.
  • Able to use a DISKUS™ inhaler
  • Able perform reproducible lung function tests at Visit 1

Inclusion criteria treatment period:

  • % predicted > 70%
  • ACT score \< 25 after run-in period

Exclusion criteria run-in period:

  • Hospitalised for asthma within 4 weeks prior to Visit 1
  • Acute upper respiratory tract infection or a lower respiratory tract infection within 4 weeks prior to Visit 1
  • Oral, parental or depot within 4 weeks prior to Visit 1
  • Hepatic impairment or other significant disease

Exclusion criteria treatment period:

  • Non-compliance (\< 70%)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    arm 1

    Drug: FLIXOTIDE and SERETIDE

Interventions

  • DrugFLIXOTIDE and SERETIDE

    Drug page: Fluticasone

    comparator

06

What researchers measure

Primary outcomes

  1. Mean change in neutrophil priming in blood as assessed by marker A17

    Time frame: on going

Secondary outcomes

  1. Activation in markers such as A27, CD11b, L-selection, CD16, CD32, VLA-4 and CD66b in whole blood- Cytokine/chemokine determination by multiplex assay in cell free serum- Asthma control measured - Lung function: FEV1, FVC and PEF- eNO

    Time frame: on going

07

Study locations

2 sites
  • GSK Investigational Site
    Utrecht, 3582 KE, Netherlands
  • GSK Investigational Site
    Utrecht, 3584 CX, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2007
First posted
Apr 4, 2007
Start
Dec 2007
Primary completionEst.
Dec 2007
CompletionEst.
Dec 2007
Last update
Apr 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00456313
Lead sponsor
GlaxoSmithKline
First posted
Apr 4, 2007
Start date
Dec 2007
Primary completion
Dec 2007 (estimated)
Completion
Dec 2007 (estimated)
Last update
Apr 17, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion